You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020160020
Dec 20203403
Jan 202144013
Feb 20213409
Mar 202182010
Apr 20217609
May 202113019
Jun 20210013
Jul 20210017
Aug 20210019
Sep 20210016
Oct 202138029
Nov 202187024
Dec 20214405
Jan 202280020
Feb 20224209
Mar 2022104015
Apr 202286012
May 20226804
Jun 2022130011
Jul 2022104014
Aug 2022126014
Sep 20221516064
Oct 2022460023
Nov 2022162012
Dec 2022174011
Jan 20235806
Feb 20237207
Mar 20237209
Apr 202358014
May 20236405
Jun 20235006
Jul 202354010
Aug 20234205
Sep 20238003
Oct 20233804
Nov 20239206
Dec 20236603
Jan 20245602
Feb 20243606
Mar 20244806
Apr 20245403
May 20244604
Jun 20247605
Jul 20245804
Aug 20245608
Sep 20245805
Oct 20244405
Nov 20245206
Dec 20244205
Jan 20254804
Feb 20251805
Mar 2025001
Apr 2025007
May 2025004
Jun 2025103
Total51030576